NZ527173A - Specific human antibodies for selective cancer therapy - Google Patents
Specific human antibodies for selective cancer therapyInfo
- Publication number
- NZ527173A NZ527173A NZ527173A NZ52717301A NZ527173A NZ 527173 A NZ527173 A NZ 527173A NZ 527173 A NZ527173 A NZ 527173A NZ 52717301 A NZ52717301 A NZ 52717301A NZ 527173 A NZ527173 A NZ 527173A
- Authority
- NZ
- New Zealand
- Prior art keywords
- human antibodies
- cancer therapy
- specific human
- selective cancer
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75118100A | 2000-12-29 | 2000-12-29 | |
PCT/US2001/049440 WO2002059264A2 (fr) | 2000-12-29 | 2001-12-31 | Anticorps humains specifiques pour la therapie selective du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ527173A true NZ527173A (en) | 2006-03-31 |
Family
ID=25020844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ527173A NZ527173A (en) | 2000-12-29 | 2001-12-31 | Specific human antibodies for selective cancer therapy |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1353937A4 (fr) |
JP (1) | JP2004524023A (fr) |
KR (1) | KR20030091952A (fr) |
CN (1) | CN100374456C (fr) |
AU (1) | AU2002246737B2 (fr) |
BR (1) | BR0116763A (fr) |
CA (1) | CA2433227A1 (fr) |
CZ (1) | CZ20031983A3 (fr) |
HU (1) | HUP0400775A2 (fr) |
IL (1) | IL156690A0 (fr) |
MX (1) | MXPA03005944A (fr) |
NZ (1) | NZ527173A (fr) |
PL (1) | PL365758A1 (fr) |
RU (1) | RU2316564C2 (fr) |
WO (1) | WO2002059264A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003279657A1 (en) * | 2002-07-01 | 2004-01-19 | Savient Pharmaceuticals, Inc. | Compositions and methods for therapeutic treatment |
AU2004256113A1 (en) * | 2003-06-30 | 2005-01-20 | Bio-Technology General (Israel) Ltd. | Specific human antibodies |
MX2007013304A (es) | 2005-04-26 | 2007-12-13 | Pfizer | Anticuerpos de p-caderina. |
EP2373343B1 (fr) * | 2008-12-19 | 2015-02-11 | Philogen S.p.A. | Immunocytokines pour thérapie tumorale avec agents chimiothérapiques |
NZ604805A (en) * | 2010-07-09 | 2014-09-26 | Affibody Ab | Polypeptides |
CN101948534B (zh) * | 2010-08-19 | 2014-05-28 | 中国科学院生物物理研究所 | 一种筛选抗体的方法 |
GB201310544D0 (en) * | 2013-06-13 | 2013-07-31 | Ucb Pharma Sa | Obtaining an improved therapeutic ligand |
HRP20211889T1 (hr) * | 2014-10-23 | 2022-03-04 | Singh Molecular Medicine, Llc | Antitijela sa jednom domenom usmjerena protiv intracelularnih antigena |
EP3233122A4 (fr) * | 2014-12-17 | 2018-09-19 | Intrexon Corporation | Fragments variables intercalés à chaîne unique |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
US20180305432A1 (en) * | 2015-10-01 | 2018-10-25 | Ospedale San Raffaele S.R.L. | Tcr and uses thereof |
EP3903818A1 (fr) * | 2015-11-19 | 2021-11-03 | Revitope Limited | Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables |
IL290517B1 (en) * | 2016-09-14 | 2024-08-01 | Teneobio Inc | CD3 binding antibodies |
KR20230140553A (ko) * | 2020-11-13 | 2023-10-06 | 프로메테우스 바이오사이언시즈, 인크. | Tl1a를 표적으로 하는 염증성 질환의 치료를 위한 방법, 시스템, 및 키트 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6140470A (en) * | 1995-06-30 | 2000-10-31 | Yale University | Human monoclonal anti-tumor antibodies |
EP0988056B1 (fr) * | 1997-01-22 | 2003-07-09 | Board Of Regents, The University Of Texas System | Methodes et compositions de thromboplastine tissulaire pour le traitement de la coagulation et des tumeurs |
-
2001
- 2001-12-31 CZ CZ20031983A patent/CZ20031983A3/cs unknown
- 2001-12-31 KR KR10-2003-7008885A patent/KR20030091952A/ko not_active Application Discontinuation
- 2001-12-31 CN CNB018228852A patent/CN100374456C/zh not_active Expired - Fee Related
- 2001-12-31 NZ NZ527173A patent/NZ527173A/xx unknown
- 2001-12-31 MX MXPA03005944A patent/MXPA03005944A/es not_active Application Discontinuation
- 2001-12-31 RU RU2003123100/13A patent/RU2316564C2/ru not_active IP Right Cessation
- 2001-12-31 BR BR0116763-4A patent/BR0116763A/pt not_active IP Right Cessation
- 2001-12-31 CA CA002433227A patent/CA2433227A1/fr not_active Abandoned
- 2001-12-31 WO PCT/US2001/049440 patent/WO2002059264A2/fr active IP Right Grant
- 2001-12-31 JP JP2002559551A patent/JP2004524023A/ja active Pending
- 2001-12-31 IL IL15669001A patent/IL156690A0/xx unknown
- 2001-12-31 HU HU0400775A patent/HUP0400775A2/hu unknown
- 2001-12-31 AU AU2002246737A patent/AU2002246737B2/en not_active Ceased
- 2001-12-31 EP EP01994329A patent/EP1353937A4/fr not_active Withdrawn
- 2001-12-31 PL PL01365758A patent/PL365758A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20030091952A (ko) | 2003-12-03 |
CZ20031983A3 (cs) | 2005-07-13 |
EP1353937A4 (fr) | 2005-04-13 |
HUP0400775A2 (en) | 2007-05-02 |
PL365758A1 (en) | 2005-01-10 |
JP2004524023A (ja) | 2004-08-12 |
MXPA03005944A (es) | 2005-04-29 |
IL156690A0 (en) | 2004-01-04 |
AU2002246737B2 (en) | 2007-03-01 |
CN100374456C (zh) | 2008-03-12 |
EP1353937A2 (fr) | 2003-10-22 |
CN1551886A (zh) | 2004-12-01 |
CA2433227A1 (fr) | 2002-08-01 |
WO2002059264A3 (fr) | 2003-03-06 |
BR0116763A (pt) | 2004-03-09 |
WO2002059264A2 (fr) | 2002-08-01 |
RU2316564C2 (ru) | 2008-02-10 |
RU2003123100A (ru) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ527173A (en) | Specific human antibodies for selective cancer therapy | |
ATE218890T1 (de) | Bispezifische moleküle mit klinischer verwendbarkeit | |
AU2003278002A1 (en) | Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics | |
TR200103756T2 (tr) | Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi. | |
NZ332566A (en) | Antigen binding fragments that specifically detect cancer cells | |
HK1076128A1 (en) | Humanized collagen antibodies and related methods | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
IL200404A (en) | Couplings of 191p4d12 (b) protein-binding antibodies and their use in the treatment of cancer | |
EA201100128A1 (ru) | АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
WO1997046589A3 (fr) | Anticorps humanises se liant au meme antigene que celui lie par l'anticorps nr-lu-13 et leur utilisation dans des procedes de preciblage | |
ATE265532T1 (de) | Monoklonaler antikörper br110 und dessen anwendung | |
HK1072272A1 (en) | Anti-ccr5 antibody | |
IL172242A0 (en) | Antibodies specific for cancer associated antigen sm5-1 and uses thereof | |
EP1881064A3 (fr) | Anticorps monoclonaux HCV-anti-cýur | |
DE60033455D1 (de) | Menschlischer monoklonaler Antikörper gegen Ep-CAM und dessen Verwendung in Krebstherapie | |
EP1581096A3 (fr) | Antigene pipa et anticorps de liaison a celui-ci | |
EP1491555A4 (fr) | Gene a region variable de chaine legere/lourde d'anticorps monoclonal hab18 anti-hepatome humain | |
AU3587599A (en) | Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo | |
AU2003226127A1 (en) | Antibody libraries | |
DK0802924T3 (da) | Lægemiddel til forlænget immunsuppression og eliminering af tumorceller | |
WO2004050849A3 (fr) | Immunotoxine recombinante et son utilisation dans le traitement de tumeurs | |
WO2005070456A3 (fr) | Diagnostic et traitement du cancer | |
WO2003072727A3 (fr) | Anticorps monoclonaux specifiques d'egfrviii, ribozymes d'egfrviii et utilisations en detection, traitement ou prevention de cancer associe a l'egfrviii | |
EP2641611A3 (fr) | Thérapie combinée | |
WO2005049652A3 (fr) | Procede de generation in vitro d'une diversite d'anticorps |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
PSEA | Patent sealed |